(Q44917828)

7 December 2017

title

Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months (English)

1 reference

7 December 2017

1 reference

0 references

1

Dick Menzies

1 reference

7 December 2017

Marie-Josée Dion

2

1 reference

7 December 2017

Barry Rabinovitch

3

1 reference

7 December 2017

Sharyn Mannix

4

1 reference

7 December 2017

Paul Brassard

5

1 reference

7 December 2017

Kevin Schwartzman

6

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

American Journal of Respiratory and Critical Care Medicine

7 December 2017

published in

1 reference

7 December 2017

volume

170

1 reference

7 December 2017

issue

4

1 reference

7 December 2017

page(s)

445-449

1 reference

Isoniazid Preventive Therapy for Tuberculosis: Decision Analysis Considering Ethnicity and Gender

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-478OC

Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-478OC

School-based screening for tuberculous infection. A cost-benefit analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-478OC

Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-478OC

Clinical practice. Latent tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-478OC

Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-478OC

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-478OC

Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-478OC

Isoniazid-associated hepatitis deaths: a review of available information

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-478OC

Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-478OC

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-478OC

Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-478OC

Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American He

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-478OC

Rifampin preventive therapy for tuberculosis in Boston's homeless.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-478OC

Factors associated with compliance in treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-478OC

Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-478OC

Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-478OC

Electronic monitoring of compliance to lipid-lowering therapy in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-478OC

Assessment of sulfonylurea adherence and metabolic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200404-478OC

10.1164/RCCM.200404-478OC

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference